RBC Capital analyst Ashish Sabadra raised the firm’s price target on CME Group (CME) to $269 from $235 and keeps a Sector Perform rating on the shares after its Q4 earnings beat. The macro uncertainty and tariffs under the new administration, increased market and rate volatility, and Treasury issuances – along with client growth, particularly in retail expansion – bode well for volume growth, though the firm continues to monitor the tough comparisons, the analyst tells investors in a research note.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group price target raised to $263 from $257 at Barclays
- CME Group Reports Record Revenue and Earnings in 2024
- Early notable gainers among liquid option names on February 12th
- CME Group reports Q4 adjusted EPS $2.52, consensus $2.45
- Cboe Global Markets price target raised to $233 from $218 at Oppenheimer